Why intratumoral CD163+ macrophages predict anti-PD-1 resistance in non-small cell lung cancer
Which biliary tract cancers benefit from regorafenib–avelumab — and which biomarkers matter?
Can trabectedin plus durvalumab help platinum-resistant ovarian carcinoma and soft tissue sarcoma?
How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
Can CD163 macrophages help select MSS colorectal cancer patients for regorafenib plus avelumab?
